Lipid Nanoparticles for Ocular Gene Delivery
Open accessThe DOI matches its Crossref record; 97 of the 99 references it cites were found in a registry or an index.
Abstract
Lipids contain hydrocarbons and are the building blocks of cells. Lipids can naturally form themselves into nano-films and nano-structures, micelles, reverse micelles, and liposomes. Micelles or reverse micelles are monolayer structures, whereas liposomes are bilayer structures. Liposomes have been recognized as carriers for drug delivery. Solid lipid nanoparticles and lipoplex (liposome-polycation-DNA complex), also called lipid nanoparticles, are currently used to deliver drugs and genes to ocular tissues. A solid lipid nanoparticle (SLN) is typically spherical, and possesses a solid lipid core matrix that can solubilize lipophilic molecules. The lipid nanoparticle, called the liposome protamine/DNA lipoplex (LPD), is electrostatically assembled from cationic liposomes and an anionic protamine-DNA complex. The LPD nanoparticles contain a highly condensed DNA core surrounded by lipid bilayers. SLNs are extensively used to deliver drugs to the cornea. LPD nanoparticles are used to target the retina. Age-related macular degeneration, retinitis pigmentosa, and diabetic retinopathy are the most common retinal diseases in humans. There have also been promising results achieved recently with LPD nanoparticles to deliver functional genes and micro RNA to treat retinal diseases. Here, we review recent advances in ocular drug and gene delivery employing lipid nanoparticles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Liposomes-protamine-DNA (LPD), in combination with a nuclear localization signal (NLS) peptide and a transactivator of transcription (TAT) peptide, make cell-specific and efficient gene delivery with sustained gene expression [35].”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.
Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., Northrop, J. P., Ringold, G. M., & Danielsen, M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7413 · Cited by 4,978 · cited 1×
“In the final analysis, liposomes depend on continually improving the formulation of the nanoparticles’ coating and DNA design to increase the transfection efficiency [76,77].”
BackgroundDiffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664 · cited 1×
“Liposomes were first identified in 1965 [63], and were successfully applied as cationic liposome complexes via intravenous DNA delivery into adult mice in 1993.”
Jain, P. K., Huang, X., El-Sayed, I. H., & El-Sayed, M. A. (2008) · Accounts of Chemical Research · doi:10.1021/ar7002804 · Cited by 4,215 · cited 1×
“Therefore, liposomes are artificial phospholipid bilayers; as a result, liposomes have biocompatible characteristics [49,50].”
BackgroundIn Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse
Schwarze, S. R., Ho, A., Vocero-Akbani, A., & Dowdy, S. F. (1999) · Science · doi:10.1126/science.285.5433.1569 · Cited by 2,416 · cited 1×
“The TAT-fusions have been shown to cross the blood–brain barrier [81].”
BackgroundSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“In clinical trials, three independent groups reported vision improvements upon the viral-mediated delivery of the Rpe65 gene in patients with Rpe65-associated Leber’s congenital amaurosis (LCA) [89–91].”
BackgroundNew-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“In clinical trials, three independent groups reported vision improvements upon the viral-mediated delivery of the Rpe65 gene in patients with Rpe65-associated Leber’s congenital amaurosis (LCA) [89–91].”
BackgroundThe Basic Science of Gene Therapy
Mulligan, R. C. (1993) · Science · doi:10.1126/science.8493530 · Cited by 1,741 · cited 1×
“The success of gene therapy relies on the development of efficient, non-toxic gene carriers that can encapsulate and deliver foreign genetic materials into specific cell types [26].”
BackgroundFutaki, S., Suzuki, T., Ohashi, W., Yagami, T., Tanaka, S., Ueda, K., & Sugiura, Y. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007540200 · Cited by 1,662
Green, M., & Loewenstein, P. M. (1988) · Cell · doi:10.1016/0092-8674(88)90262-0 · Cited by 1,553 · cited 1×
“In 1988, the first CPP was sequenced from an HIV-1-encoded cell-penetrating transactivator of transcription (TAT) peptide, and delivered efficiently through cell membranes; TAT has been widely applied since then [83–85].”
Method
Research works printed but not linked: 1
- Immordino, 2006, Stealth liposomes, review of the basic science, rationale, and clinical applications, existing and potential, Int. J. Nanomedicine., 1, 297
Cited by
Solid lipid nanoparticles: a review on recent perspectives and patents
Paliwal, R., Paliwal, S. R., Kenwat, R., Kurmi, B. D., & Sahu, M. K. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1720649 · Cited by 337
“20 Ocular gene delivery Lipid Nanoparticles for Ocular Gene Delivery [47] 21 Topical immunization A highlight on lipid based nanocarriers for transcutaneous immunization [48] 22 Nucleic acid delivery Solid lipid nanoparticles as nucleic acid delivery system: properties and molecular mechanisms [49] 23 Topical delivery…”
BackgroundPrasad, M., Lambe, U. P., Brar, B., Shah, I., J, M., Ranjan, K., Rao, R., Kumar, S., Mahant, S., Khurana, S. K., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.026 · Cited by 327
A review on recent drug delivery systems for posterior segment of eye
Nayak, K., & Misra, M. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.138 · Cited by 225
Ocular delivery of proteins and peptides: Challenges and novel formulation approaches
Mandal, A., Pal, D., Agrahari, V., Trinh, H. M., Joseph, M., & Mitra, A. K. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.01.008 · Cited by 225
“Both SLNs and NLCs have shown potential in delivering small molecules to ocular tissues [171-173].”
BackgroundNanomedicines to Deliver mRNA: State of the Art and Future Perspectives
Gómez-Aguado, I., Rodríguez-Castejón, J., Vicente-Pascual, M., Rodríguez-Gascón, A., Solinís, M. Á., & del Pozo-Rodríguez, A. (2020) · Nanomaterials · doi:10.3390/nano10020364 · Cited by 223
Metadata
- Authors
- Wang, Y., Rajala, A., & Rajala, R.
- Affiliations
- Dean McGee Eye Institute (US)
- Corresponding author
- Rajala, Raju
- Venue
- Journal of Functional Biomaterials
- Publisher
- MDPI AG
- Published
- 2015-06-08
- Volume
- 6
- Issue
- 2
- Pages
- 379-394
- ISSN
- 2079-4983 (ISSN-L)
- PMC
- PMC4493518
- OpenAlex
- W1506466933
- Cited by
- 93
- References
- 99
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 2 · 2023: 9 · 2022: 12 · 2021: 12 · 2020: 6 · 2019: 7 · 2018: 10 · 2017: 7 · 2016: 9 · 2015: 3
- FWCI
- 0.94
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Journal of Functional Biomaterials (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- NIH (EY016507, EY00871, EY021725)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- lipid nanoparticles, ocular gene delivery, solid lipid nanoparticles, lipoplexes, liposomes, corneal drug delivery, retinal gene therapy, age-related macular degeneration, retinitis pigmentosa, diabetic retinopathy, microRNA delivery, retinal disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipid Nanoparticles for Ocular Gene Delivery. https://app.cochat.ai/papers/10.3390/jfb6020379
- The paper
- Wang, Y., Rajala, A., & Rajala, R. (2015). Lipid Nanoparticles for Ocular Gene Delivery. Journal of Functional Biomaterials. https://doi.org/10.3390/jfb6020379
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.